Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Glipizide tablets and application thereof

A technology of glipizide tablets and glipizide, which is applied in the direction of non-active ingredient medical preparations, medical preparations containing active ingredients, pill delivery, etc., and can solve the problem of lowering blood sugar by glipizide and arctiin There are no other problems, and the product has less impurities, excellent effect and good uniformity.

Inactive Publication Date: 2019-12-31
仁和堂药业有限公司
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the prior art, there is no scheme of combining glipizide and arctiin to lower blood sugar, let alone a scheme of preparing the two together into tablets

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Glipizide tablets and application thereof
  • Glipizide tablets and application thereof
  • Glipizide tablets and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] A glipizide tablet, its prescription is shown in Table 1.

[0024] Table 1

[0025]

[0026] Tablet preparation process:

[0027] ①Pretreatment of raw and auxiliary materials:

[0028] Receive qualified raw materials and auxiliary materials, pass stearic acid through an 80-mesh sieve, and set aside.

[0029] ②Weighing:

[0030] Weigh glipizide, arctiside, lactose monohydrate, microcrystalline cellulose, cornstarch, stearic acid according to the recipe quantity, for subsequent use;

[0031] ③Mix:

[0032] Mix 50g of glipizide and lactose monohydrate in equal amounts (about 3 times) (100g+200g+400g), each time for 5 minutes, and place the remaining amount of lactose monohydrate together in a three-dimensional motion Mixing was carried out in a mixer, rotating speed: 12 rpm, mixing time: 1 h.

[0033] Take it out, pass through a 30-mesh sieve to remove agglomerates, and then place it in a three-dimensional motion mixer to mix for 3 hours. Add 10 g of arctiside, 1...

Embodiment 2

[0039] Sample quality and dissolution testing.

[0040] The product of the present invention is tested for correlation, content and dissolution. The specific data are as follows 2:

[0041] Table 2 Test results of finished products

[0042]

[0043] Table 3 Dissolution curve results of finished products in four media

[0044]

Embodiment 3

[0050] Animal experiment.

[0051] Animal grouping: 40 Kunming strain mice were selected, half male and half female, weighing 19.4±2.5g.

[0052] The blank control group, 5 males and 5 males, was given the same amount of normal saline without modeling;

[0053] Model control group: 5 males and 5 males, no drug for modeling, but the same amount of normal saline;

[0054] Comparative example group: 5 males and 5 males, modeled and given the drug of Comparative Example 1;

[0055] Experimental group: 5 males and 5 males, modeled and given the medicine of Example 1.

[0056] Modeling of diabetic mice: The mice were fasted for 12 hours and injected intraperitoneally with 100 mg / kg of alloxan.

[0057] Administration: After 2 days of modeling, the rats were given continuous intragastric administration for 8 days, and the dosage was 3 mg / kg.

[0058] Blood glucose determination: After 1 h of administration on the 8th day, 1 mL of blood was collected from the inner canthus of the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the field of a pharmaceutical technology, and discloses Glipizide tablets. The Glipizide tablets consist of the following raw materials of Glipizide, arctiin, lactose monohydrate, microcrystalline cellulose, corn starch, silicon dioxide and stearic acid. The arctiin active component is added to the tablets, through joint action of the arctiin and the Glipizide, the effectis good, and further clinical testing can be performed for verification.

Description

technical field [0001] The invention belongs to the technical field of pharmacy, and in particular relates to a glipizide tablet and use thereof. Background technique [0002] Glipizide, chemical name 1-cyclohexyl-3-{4-[2-(5-methylpyrazine-2-amide)-ethyl]benzenesulfonyl}urea, molecular formula: C21H27N5O4S, molecular weight is 445.54. Glipizide is a second-generation sulfonylurea oral hypoglycemic agent. It can promote islet β cells to secrete insulin and enhance the effect of insulin on target tissues; it can also stimulate islet α cells to inhibit glucagon secretion, and also inhibit hepatic glycogenolysis, promote muscle utilization and consume glucose. [0003] After taking the common glipizide preparation, the blood sugar fluctuates greatly, and there are many adverse reactions, and the patient needs to take the medicine several times a day, and the compliance is poor. Most of the existing technologies are improved from the formulation itself, including the preparati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61K9/20A61K31/64A61K47/38A61K47/36A61K47/26A61K47/04A61P3/10
CPCA61K31/7048A61K31/64A61K9/2059A61K9/2054A61K9/2018A61K9/2009A61K9/2095A61P3/10
Inventor 林凡儒郭增光王明涛刘倩
Owner 仁和堂药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com